In a perspective in this week’s New England Journal of Medicine, Drs. Lisa Schwartz and Steven Woloshin , faculty at Dartmouth University , persuasively argue that the answer to question posed in the title is YES. Schwartz and Woloshin note that when the FDA reviews a drug, expert reviewers consider a wealth of data about the benefits and side effects of the drug. They also raise questions, make judgments, and make statements about their degree of certainty that the benefits of the drug outweigh the risks. However, effectiveness and harm data that patients and their providers might want to see often do not make it to the drug label. Opinions of the expert reviewer, including their degree of uncertainty about the drug, would be of great interest but these virtually never make it to the label. This information is contained in FDA documents, but these voluminous documents are not practically accessible. This article is a quick and fascinating read that has 3 fascinating examples t